Merus announces first patient dosed in Phase 2 trial of petosemtamab in 2L CRC

Merus announced that the first patient has been dosed in the Company’s phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in second line, 2L, metastatic colorectal cancer, mCRC. Petosemtamab is a Biclonics targeting EGFR and LGR5. The phase 2, open-label trial will evaluate the safety and preliminary antitumor of petosemtamab and a regimen of chemotherapy in 2L mCRC. The study will enroll approximately 40 patients not previously treated with EGFR inhibitors and whose tumors do not harbor a KRAS mutation. “We’re pleased by the progress we are making across the petosemtamab clinical development program,” said Peter Silverman, Chief Operating Officer. “Petosemtamab continues to demonstrate meaningful clinical activity in head and neck cancer, and we are excited by the opportunity to expand into mCRC and investigate this novel potential treatment for patients struggling with this devastating disease.”